Table 4
StudyCaseBaselineWeek 24
A: Gorman Diplopia Score in patients who received teprotumumab
 3130
 3230
 3311
 2431
 2531
 2632
 2730
 2820
 2930
 21012
 Mean2.30.7
 SD1.10.8
B: Gorman diplopia score in patients who received Placebo
 Phase 3102
 Phase 3222
 Phase 3333
 Phase 3400
 Phase 3533
 Phase 3632
 Phase 2713
 Phase 2833
 Phase 2902
 Phase 21000
 Phase 21111
 Phase 21213
 Mean1.42
 SD1.31.1